Patents by Inventor Franck Galland

Franck Galland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of VNN1 as a biomarker and a therapeutic target in sarcomas
    Patent number: 11579147
    Abstract: Sarcomas are rare malignant tumors arising from the mesenchymal tissues at all body sites. The inventors show that in a mouse model of p16/p19 deficiency prone to tumor development, the absence of the mouse pantetheinase Vnn1 enhances the frequency of aggressive fibrosarcomas. They also show that reintroduction of a catalytically active form of the Vnn1 pantetheinase limits tumor growth in vivo. Interestingly, VNN1 expression in human sarcomas is associated with reduced aggressiveness and lower risk of metastatic relapse in patients. In conclusion, Vnn1 represents a novel marker of sarcoma and may modulate tumor aggressiveness by sustaining myofibroblast cell differentiation, thereby limiting evolution towards undifferentiated tumors. The present invention relates to the use of Vnn1 as a biomarker and a therapeutic target in sarcomas.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: February 14, 2023
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Université d'Aix Marseille, Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard, Centre Leon Bernard
    Inventors: Philippe Naquet, Franck Galland, Virginie Millet, Jean-Yves Blay, Caroline Giessner
  • USE OF VNN1 AS A BIOMARKER AND A THERAPEUTIC TARGET IN SARCOMAS
    Publication number: 20210364518
    Abstract: Sarcomas are rare malignant tumors arising from the mesenchymal tissues at all body sites. The inventors show that in a mouse model of p16/p19 deficiency prone to tumor development, the absence of the mouse pantetheinase Vnn1 enhances the frequency of aggressive fibrosarcomas. They also show that reintroduction of a catalytically active form of the Vnn1 pantetheinase limits tumor growth in vivo. Interestingly, VNN1 expression in human sarcomas is associated with reduced aggressiveness and lower risk of metastatic relapse in patients. In conclusion, Vnn1 represents a novel marker of sarcoma and may modulate tumor aggressiveness by sustaining myofibroblast cell differentiation, thereby limiting evolution towards undifferentiated tumors. The present invention relates to the use of Vnn1 as a biomarker and a therapeutic target in sarcomas.
    Type: Application
    Filed: September 25, 2018
    Publication date: November 25, 2021
    Inventors: Philippe NAQUET, Franck GALLAND, Virginie MILLET, Jean-Yves BLAY, Caroline GIESSNER
  • Method of treatment of an inflammatory disorder with a Vanin-1 antagonist
    Publication number: 20040247524
    Abstract: The present invention relates to the screening of Vanin-1 antagonists useful for the treatment of an inflammatory disorder, in particular intestinal inflammation, and to a method treatment of an inflammatory disorder with such a Vanin-1 antagonist.
    Type: Application
    Filed: June 5, 2003
    Publication date: December 9, 2004
    Inventors: Philippe Naquet, Franck Galland, Florent Martin, Max De Reggi, Bouchra Di Reggi, Marie-France Penet, Giuseppina Pitari, Sylvestro Dupre